IPO
Biotech IPO Market Sees Rare Upsurge with Triple Listing Success
Biotech IPO, Market Flux, Tripleheader, Bicara Therapeutics, Zenas BioPharma, MBX Biosciences, Stock Surge, Pharmaceutical Industry
BioAge Labs Files for IPO to Advance Obesity Treatment Candidate
BioAge Labs, IPO, obesity treatment, weight loss drugs, azelaprag, Eli Lilly, cardiometabolic biotech
BioAge Labs Files for $100 Million IPO to Advance Obesity Treatment Candidate Azelaprag
BioAge Labs, IPO, Obesity Treatment, Azelaprag, Eli Lilly, Novo Nordisk, Clinical Trials
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
MBX Biosciences Enters IPO Queue Amid End-of-Summer Rush
MBX Biosciences, IPO, NASDAQ, peptide therapeutics, biotech, public offering
Bicara and Zenas File for IPOs to Advance Late-Phase Cancer and Autoimmune Treatments
Bicara Therapeutics, Zenas BioPharma, IPO, cancer treatment, autoimmune disease, biotech, pharmaceuticals
TYK Medicines Secures $74M in Hong Kong IPO to Advance EGFR Cancer Therapy
TYK Medicines, IPO, EGFR cancer therapy, Hong Kong, biotech funding
OS Therapies Refiles IPO for $6M to Fund Phase 2 HER2 Drug and Preclinical ADCs
OS Therapies, IPO, HER2 drug, preclinical ADCs, immunotherapy, NYSE American exchange
Telix Pharmaceuticals Raises $400M in Bond Sale Amid IPO Uncertainty
Telix Pharmaceuticals, Bond Sale, IPO, Radiopharma, Funding
Artiva Biotherapeutics Seeks $116M in Second IPO Attempt for Cell Therapy Development
Artiva Biotherapeutics, IPO, cell therapy, AlloNK, systemic lupus erythematosus, autoimmune diseases